A novel cancer therapy approach targeting microtubule function

Cancer Biology and Therapy

Volumn 5, Issue 12, 2006, Pages 1721-1723

  Murphy, Maureen E ^a   Cassimeris, Lynne ^b  

^a FOX CHASE CANCER CENTER   (United States)

^b LEHIGH UNIVERSITY   (United States)

Author keywords

Apoptosis; Microtubules; siRNA; Stathmin; Survivin

Indexed keywords

ADENOVIRUS VECTOR; ANTISENSE OLIGONUCLEOTIDE; PACLITAXEL; PROTEIN INHIBITOR; SHEPHERDIN; SMALL INTERFERING RNA; STATHMIN; SURVIVIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CYTOSKELETON; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; MICROTUBULE; MICROTUBULE ASSEMBLY; MITOSIS; NONHUMAN; NOTE; OVARY CANCER; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; VIRAL GENE DELIVERY SYSTEM;

EID: 33846962838     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.12.3736     Document Type: Note

References (32)

1. Wilson L, Panda D, Jordan MA. Modulation of microtubule dynamics by drugs: a paradigm for the actions of cellular regulators. Cell Struct Funct 1999; 24:329-35.
2. Cassimeris L. The oncoprotein 18/stathmin family of microtubule destabilizers. Curr Opin Cell Biol 2002; 14:18-24.
3. Rubin CI, Atweh GF. The role of stathmin in the regulation of the cell cycle. J Cell Biochem 2004; 93:242-50.
4. Belmont LD, Mitchison TJ. Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules. Cell 1996; 84:623-31.
5. Jourdain L, Curmi P, Sobel A, Pantaloni D, Carlier MF. Stathmin: a tubulin sequestering protein which forms a ternary T2S complex with two tubulin molecules. Biochemistry 1997; 36:10817-21.
6. Howell B, Larsson N, Gullberg M, Cassimeris L. Dissociation of the tubulin sequestering and microtubule catastrophe promoting activities of oncoprotein 18/stathmin. Mol Biol Cell 1999; 10:105-18.
7. Wittmann T, Bokoch GM, Waterman Storer CM. Regulation of microtubule destabilizing activity of Op18/stathmin downstream of Rac1. J Biol Chem 2004; 279:6196-203.
8. Baldassarre G, Belletti B, Nicoloso MS, Schiappacassi M, Vecchione A, Spessotto P, Morrione A, Canzonieri V, Colombatti A. p27(Kip1) stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell 2005; 7:51-63.
9. Ng DC, Lin BH, Lim CP, Huang G, Zhang T, Poli V, Cao X. Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. J Cell Biol 2006; 172:245-57.
10. Ozon S, Guichet A, Gavet O, Roth S, Sobel A. Drosophila stathmin: a microtubule destabilizing factor involved in nervous system formation. Mol Biol Cell 2002; 13:698-710.
11. Marklund U, Osterman O, Melander H, Bergh A, Gullberg M. The phenotype of a "Cdc2 kinase target site deficient" mutant of oncoprotein 18 reveals a role of this protein in cell cycle control. J Biol Chem 1994; 269:30626-35.
12. Marklund U, Larsson N, Gradin HM, Brattsand G, Gullberg M. Oncoprotein 18 is a phosphorylation responsive regulator of microtubule dynamics. EMBO J 1996; 15:5290-8.
13. Budde PP, Kumagai A, Dunphy WG, Heald R. Regulation of Op18 during spindle assembly in Xenopus egg extracts. J Cell Biol 2001; 153:149-58.
14. Niethammer P, Bastiaens P, Karsenti E. Stathmin tubulin interaction gradients in motile and mitotic cells. Science 2004; 303:1862-6.
15. Schubart UK, Yu J, Amat JA, Wang Z, Hoffmann MK, Edelmann W. Normal development of mice lacking metablastin (P19), a phosphoprotein implicated in cell cycle regulation. J Biol Chem 1996; 271:14062-6.
16. Holmfeldt P, Brannstrom K, Stenmark S, Gullberg M. Aneugenic activity of Op18/stathmin is potentiated by the somatic Q18 - >e mutation in leukemic cells. Mol Biol Cell 2006; 17:2921-30.
17. Mistry SJ, Bank A, Atweh GF. Targeting stathmin in prostate cancer. Mol Cancer Ther 2005; 4:1821-9.
18. Zhang HZ, Wang Y, Gao P, Lin F, Liu L, Yu B, Ren JH, Zhao H, Wang R. Silencing Stathmin Gene Expression by Survivin Promoter Driven siRNA Vector to Reverse Malignant Phenotype of Tumor Cells. Cancer Biol Ther 2006; In press.
19. Mistry SJ, Benham CJ, Atweh GF. Development of ribozymes that target stathmin, a major regulator of the mitotic spindle. Antisense Nucleic Acid Drug Dev 2001; 11:41-9.
20. Iancu C, Mistry SJ, Arkin S, Wallenstein S, Atweh GF. Effects of stathmin inhibition on the mitotic spindle. J Cell Sci 2001; 114:909-16.
21. Alli E, Yang JM, Hait WN. Silencing of stathmin induces tumor suppressor function in breast cancer cell lines harboring mutant p53. Oncogene 2006; In press.
22. Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, Rago C, Lal A, Wang CJ, Beaudry GA, Ciriello KM, Cook BP, Dufault MR, Ferguson AT, Gao Y, He TC, Hermeking H, Hiraldo SK, Hwang PM, Lopez MA, Luderer HF, Mathews B, Petroziello JM, Polyak K, Zawel L, Kinzler KW, et al. Analysis of human transcriptomes. Nat Genet 1999; 23:387-8.
23. Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 2006; 5:1087-98.
24. Bao R, Connolly DC, Murphy M, Green J, Weinstein JK, Pisarcik DA, Hamilton TC. Activation of cancer specific gene expression by the survivin promoter. J Natl Cancer Inst 2002; 94:522-8.
25. Chen JS, Liu JC, Shen L, Rau KM, Kuo HP, Li YM, Shi D, Lee YC, Chang KJ, Hung MC. Cancer specific activation of the survivin promoter and its potential use in gene therapy. Cancer Gene Ther 2004; 11:740-7.
26. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti apoptotic survivin gene by wild type p53. J Biol Chem 2002; 277:3247-57.
27. Ahn J, Murphy M, Kratowicz S, Wang A, Levine AJ, George DL. Down regulation of the stathmin/Op18 and FKBP25 genes following p53 induction. Oncogene 1999; 18:5954-8.
28. Fraser AG, James C, Evan GI, Hengartner MO. Caenorhabditis elegans inhibitor of apoptosis protein (IAP) homologue BIR 1 plays a conserved role in cytokinesis. Curr Biol 1999; 9:292-301.
29. Rosa J, Canovas P, Islam A, Altieri DC, Doxsey SJ. Survivin modulates microtubule dynamics and nucleation throughout the cell cycle. Mol Biol Cell 2006; 17:1483-93.
30. Tulu US, Fagerstrom C, Ferenz NP, Wadsworth P. Molecular requirements for kinetochore associated microtubule formation in mammalian cells. Curr Biol 2006; 16:536-41.
31. Plescia J, Salz W, Xia F, Pennati M, Zaffaroni N, Daidone MG, Meli M, Dohi T, Fortugno P, Nefedova Y, Gabrilovich DI, Colombo G, Altieri DC. Rational design of shepherdin, a novel anticancer agent. Cancer Cell 2005; 7:457-68.
32. Iancu C, Mistry SJ, Arkin S, Atweh GF. Taxol and anti stathmin therapy: a synergistic combination that targets the mitotic spindle. Cancer Res 2000; 60:3537-41.